ACCEPTING DOCTORAL STUDENTS
The Aubé laboratory uses synthetic chemistry to enable the study of biological pathways and as starting points for drug discovery. Current efforts in the group include the study of new opioids lacking side effects, new approaches for the treatment of tuberculosis, androgen biosynthesis inhibitor discovery, the search for RNA-protein interaction inhibitors, and the development of new synthetic methods.
Axtman is currently a research assistant professor in the Chemical Biology and Medicinal Chemistry Department in the UNC Eshelman School of Pharmacy. At the SGC-UNC, she leads the design of novel chemical probes for understudied protein kinases that will be openly shared with collaborators to facilitate target discovery in human disease-relevant assays. When she’s not in the lab, Axtman can most often be found at the gym preparing for the next CrossFit or GRID competition with her teammates.
ACCEPTING DOCTORAL STUDENTS
Albert Bowers received his PhD in organic chemistry (synthetic methods) from the University of Illinois at Chicago. He carried out postdoctoral research (total synthesis) at Colorado State University before moving as an NIH sponsored fellow to Harvard Medical School (biosynthesis). He is a member of the UNC Lineberger Comprehensive Cancer Center and affiliate member of the Center for Integrative Chemical Biology and Drug Discovery.
ACCEPTING DOCTORAL STUDENTS
The Drewry lab in focused on designing, synthesizing, evaluating, and sharing small molecule chemical probes for protein kinases. These tools are used to build a deeper understanding of disease pathways and facilitate identification of important targets for drug discovery. Through wide ranging partnerships with academic and industrial groups, the Drewry lab is building a Kinase Chemogenomic Set (KCGS) that is available to the community for screening.
Research in the Frankowski lab uses synthetic chemistry to develop new approaches for the treatment of unmet medical needs. Our current efforts focus on programs to treat metastatic cancer, hepatitis C virus infection and the development of chemical tools for studying dopamine and sigma receptors.
ACCEPTING DOCTORAL STUDENTS
The Frye lab focuses on chemical biology of chromatin regulation with an emphasis on proteins that bind methylated lysine, and collaborative oncology drug discovery with faculty in the Lineberger Cancer Center. Students in the Frye lab develop expertise in synthetic chemistry, biophysical techniques, assay development, structure-based drug design and medicinal chemistry.
Alexander Golbraikh’s research is geared toward the development and application of computational methods for drug discovery and design. Revolutionary development of information and communication technologies during the last few decades has dramatically changed our capabilities of collecting and accessing all sorts of data.
Dr. Goto’s research is centered around the mechanism of action studies on the novel natural products and their derivatives, which show selective bioactivities against cancer, especially focused on breast cancer and multidrug-resistant carcinomas.
ACCEPTING DOCTORAL STUDENTS
The Hathaway lab was established at UNC with a founding idea that the group could make a contribution to understanding dynamic epigenetic processes by using unique chemical biology approaches they pioneered. Through the combination of protein bioengineering, synthetic organic chemistry, and mammalian cell-based model systems, they have created platforms that use chemically tethered enzymatic recruitment to specific chromatin loci to produce a host of mechanistic insights. The Hathaway group also has drug discovery programs to identify new small molecules that inhibit disease relevant epigenetic pathways both for research purposes and as potential future therapeutics.
ACCEPTING DOCTORAL STUDENTS
The James lab is interested in modulating the activity of chromatin reader proteins with small-molecule ligands, specifically potent and selective chemical probes, in order to open new avenues of research in the field of chromatin biology and potentially translate to compounds of therapeutic value. They are also interested in applying novel probe-based techniques, such as affinity labeling technologies, to the study of epigenetic regulators.
As Assistant Dean for Graduate Education, Mike Jarstfer is the Director of Graduate Studies for Pharmaceutical Sciences PhD Program and in this role advances innovative approaches to enhance graduate training. The Jarstfer lab is interested in targeting telomere biology for aging disorders and cancer treatment strategies and exploring the mechanism of oxytocin in controlling social behavior.
Kireev lab develops and applies computational tools to advance our understanding of complex biological systems and discover therapies for unmet medical needs.
ACCEPTING DOCTORAL STUDENTS
The Lawrence lab works to understand the biochemical processes of the cell by studying them as they happen in the cell as opposed to studying them in vitro. He currently focuses on applying his discoveries to cancer detection and treatment and, to a more limited extent, inflammatory diseases.
ACCEPTING DOCTORAL STUDENTS
Andrew Lee studies the role of conformational dynamics in protein function, conformational changes, enzyme catalysis, drug binding, and allostery. His laboratory uses a variety of biophysical and biochemical tools, especially NMR spectroscopy. NMR spectroscopy is a powerful approach that yields atomic-resolution molecular information and is uniquely sensitive to molecular fluctuations over a broad range of timescales.
ACCEPTING DOCTORAL STUDENTS
The K.H. Lee Natural Products Research Laboratories (NPRL) engage in research using medicinal chemistry-based methods to discover new drugs from herbal medicines, particularly Traditional Chinese Medicine. The NPRL combines the fields of the most advanced natural products chemistry and synthetic medicinal chemistry as well as cutting-edge life science technologies in its new drug discovery and design program. An iterative process of bioactivity screening/synthetic modification is used to optimize herbal medicine-based bioactive natural products and their analogs as clinical trials drug candidates for treating cancer and AIDS, as well as other diseases.
ACCEPTING DOCTORAL STUDENTS
Research in the Jian Liu group is focused on glycobiology and glycobiochemistry, an emerging field that emphasizes the biological functions of carbohydrates. We are particularly interested in understanding the biosynthetic mechanism of sulfated polysaccharides known as heparan sulfate and heparin.
ACCEPTING DOCTORAL STUDENTS
The Liu laboratory’s research interests focus on the development and application of novel drug target-binding affinity molecules by integrating directed molecular selection and evolution, ligand design and engineering, in vitro cellular and signaling characterization, and in vivo therapeutic efficacy studies in tumor mouse models. The Liu laboratory has extensive experiences in the design, synthesis, characterization, and delivery of diagnostic and therapeutic agents based on both polypeptides and polynucleotides.
ACCEPTING DOCTORAL STUDENTS
The McGinty lab studies molecular mechanisms of chromatin signaling. By pairing atomic precision protein chemistry with high resolution structural biology, they aim to understand how the nucleosome functions as a signaling hub for gene expression, DNA replication, and DNA damage repair in development and disease.
The Morris-Natschke laboratory focuses on natural product chemistry in collaboration with the Natural Products Research Laboratories at UNC. The goal is to support strong rational drug discovery and development research programs, particularly focusing on AIDS and cancer.
ACCEPTING DOCTORAL STUDENTS
The Pattenden lab develops innovative techniques in chromatin-based therapeutic target discovery and cancer diagnostics. Our research program enables discovery of novel molecular targets, pathways and mechanisms. Our central strategy exploits tumor-specific changes in chromatin accessibility, a universal feature that is directly linked with transcriptional activation, DNA damage repair, replication, RNA processing, and nuclear organization.
ACCEPTING DOCTORAL STUDENTS
The Pearce lab utilizes numerous methods for conducting early drug and chemical probe discovery research. These techniques include development of biochemical and cell assays, high-throughput screening, DNA-encoded library technology, peptide phage display, and mechanistic/biophysical studies. Targets for these discovery campaigns include proteins involved in epigenetic regulation, signal transduction, and enzymatic modifications. Projects are typically collaborative efforts with labs across the UNC campus and span several therapeutic areas, with a particular focus on oncology targets.
Bryan Roth, PhD, MD, is a professor in the Division of Chemical Biology and Medicinal Chemistry and in the Department of Pharmacology. He is also the director of the NIMH Psychoactive Drug Screening Program. The Roth Lab studies the structure and function of G-Protein coupled receptors (GPCRs).
Scott Singleton is engaged in educational innovation and research. His work attempts to build on what is understood about memory and attention to devise, test, and implement effective teaching and learning strategies. His current work focuses on teaching that positively affects student engagement in the classroom, identifying core basic science concepts that serve as threshold concepts for pharmacy students, and evaluating the transfer of learning between courses in the professional PharmD program.
ACCEPTING DOCTORAL STUDENTS
Alex Tropsha, Ph.D., is an expert in the fields of computational chemistry, cheminformatics and data science. His laboratory develops new methodologies, software tools and applications in the areas of computer-assisted drug design, chemical toxicology, materials informatics, text mining, and health care informatics.
Qunzhao Wang has created a technology that visualizes the behavior of a specific family of enzymes (protein kinases) in living cells. These enzymes have been implicated in a wide variety of disease states, including several forms of cancer.
The Wang lab is interested in developing drug leads/candidates for kinase, phosphate kinase and protein targets identified by UNC faculty and external investigators. We have successfully used the structure- and/or ligand-based drug design approaches to deliver compounds to clinic (MerTK inhibitors such as MRX-2843) or licensing (IDH1 inhibitor, co-developed with NCATs). We will continue to apply the similar approaches for drug discovery towards new targets.
The Willson laboratory is home to the US site of the SGC, an open science consortium that accelerates research on the lesser studied regions of the genome. The laboratory works closely with pharma companies and academic investigators to develop small molecule chemical probes for hundreds of dark kinases that are openly shared with the scientific community. Current research has led to the development of the Kinase Chemogenomic Set (KCGS) that contains selective inhibitors of more than 200 kinases as well as high quality chemical probes for several of the dark kinases.
Dr. Xu co-authored the Heparin study with Dr. Jian Liu and Dr. Lindhardt. Heparin is a naturally occurring polysaccharide that prevents blood clotting, or coagulation, and has been in use since the late 1930s. A polysaccharide is a long chain of carbohydrate molecules.
ACCEPTING DOCTORAL STUDENTS
The Zhang lab studies lipid signaling pathways that are involved in human disease by developing novel chemical probes and technologies. They currently focus on discovering new bioactive lipids, developing small molecule modulators and biosensors for lipid metabolizing enzymes, and applying their research results to novel diagnosis and treatment of cancer, Parkinson’s disease, and antimicrobial resistance.
The Zuercher laboratory is interested in the development and application of kinase inhibitors to uncover new biology in humans and in pathogens. They are highly collaborative in the application of medicinal chemistry and chemical biology to diverse contexts. The resulting learnings may in turn inform the discovery of medicines with new molecular mechanisms of action.
ACCEPTING DOCTORAL STUDENTS
The Aubé laboratory uses synthetic chemistry to enable the study of biological pathways and as starting points for drug discovery. Current efforts in the group include the study of new opioids lacking side effects, new approaches for the treatment of tuberculosis, androgen biosynthesis inhibitor discovery, the search for RNA-protein interaction inhibitors, and the development of new synthetic methods.
ACCEPTING DOCTORAL STUDENTS
The Lawrence lab works to understand the biochemical processes of the cell by studying them as they happen in the cell as opposed to studying them in vitro. He currently focuses on applying his discoveries to cancer detection and treatment and, to a more limited extent, inflammatory diseases.
ACCEPTING DOCTORAL STUDENTS
The McGinty lab studies molecular mechanisms of chromatin signaling. By pairing atomic precision protein chemistry with high resolution structural biology, they aim to understand how the nucleosome functions as a signaling hub for gene expression, DNA replication, and DNA damage repair in development and disease.
Bryan Roth, PhD, MD, is a professor in the Division of Chemical Biology and Medicinal Chemistry and in the Department of Pharmacology. He is also the director of the NIMH Psychoactive Drug Screening Program. The Roth Lab studies the structure and function of G-Protein coupled receptors (GPCRs).
Hal Kohn, Ph.D., received a B.S. in chemistry from the University of Michigan in 1966, and a Ph.D. in chemistry from Pennsylvania State University in 1971. He conducted postdoctoral research at Columbia University from 1971 to 1973 with Professor Ronald Breslow.
pederse2@niehs.nih.gov
Adjunct Associate Professor, UNC Eshelman School of Pharmacy
Staff Scientist, Head of Collaborative Crystallography Lab, NIEHS[/column]
Dr. Tang is a collaborating member from ViiV Healthcare with the UNC-Chapel Hill HIV Cure Center. His research is focused on discovering novel HIV latency reversal agents with better tolerability and exploring new ways to clear the latent T cells upon activation and viral particles.
